stockrow
Friday 6 November 2026
Export CTKB’s income statement to Excel — free account
Cytek Biosciences, Inc.
CTKB Healthcare Medical Devices
Cytek Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $201.5 million, up 0.52% from fiscal 2024.
- Revenue
- +1.79%
- EPS
- −17.0%
- Free cash flow
- −30.3%
- Total debt
- −84.9%
Quarter to September 2026, against a year earlier
5.82
0.42
+7.78%
Follow CTKB
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(18.05%) | (20.93%) | (23.04%) | (23.20%) | |
Piotroski F-Score |
4 | 4 | 4 | 4 | |
| (13.85%) | (15.89%) | (17.14%) | (17.26%) | ||
ROIC |
(31.26%) | (41.67%) | (46.36%) | (42.08%) | |
Return on Tangible Assets |
(20.03%) | (23.21%) | (25.63%) | (25.81%) | |
Average Days of Receivables |
113.23 | 92.79 | 87.76 | 104.04 | |
Free Cash Flow per Share |
(0.07) | (0.10) | (0.09) | (0.10) | |
Free Cash Flow |
(8.62) | (12.61) | (11.97) | (13.34) | |
Capital Expenditures |
(3.94) | (5.31) | (5.93) | (6.75) | |
| Other line items | |||||
Cash ROIC |
(1.43%) | (2.14%) | (2.05%) | (2.31%) | |
Accounts Receivable Turnover |
3.27 | 3.82 | 3.90 | 3.59 | |
Accounts Payable Turnover |
16.25 | 15.19 | 12.67 | 15.01 | |
Inventory Turnover |
2.10 | 2.07 | 1.90 | 1.81 | |
Average Days of Payables |
24.11 | 24.95 | 31.74 | 18.98 | |
Days of Inventory on Hand |
182.17 | 184.29 | 197.27 | 203.44 | |
Tax Rate |
1.23 | 1.06 | 0.97 | 1.03 | |
Research and Development Expense of Revenue |
18.10% | 17.80% | 18.03% | 18.14% | |
Selling, General and Administrative Expense of Revenue |
53.79% | 55.39% | 56.80% | 57.74% | |
Share Based Compensation of Revenue |
12.20% | 11.17% | 10.34% | 9.91% | |
Interest Coverage |
(85.20) | (98.59) | (143.10) | (562.55) | |
Operating CF/Net income |
0.07 | 0.10 | 0.07 | 0.08 | |
Depreciation/Fixed assets |
0.66 | 0.58 | 0.57 | 0.58 | |
Capex/Depreciation |
(0.33) | (0.45) | (0.50) | (0.56) | |
Revenue per Share |
1.58 | 1.59 | 1.60 | 1.59 | |
Operating CF per Share |
(0.04) | (0.06) | (0.05) | (0.05) | |
Capex per Share |
(0.03) | (0.04) | (0.05) | (0.05) | |
Capex to Sales |
0.02 | 0.03 | 0.03 | 0.03 |
Columns are period end dates · fundamentals updated 6 Nov 2026